[go: up one dir, main page]

CY1116842T1 - Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου - Google Patents

Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Info

Publication number
CY1116842T1
CY1116842T1 CY20151100622T CY151100622T CY1116842T1 CY 1116842 T1 CY1116842 T1 CY 1116842T1 CY 20151100622 T CY20151100622 T CY 20151100622T CY 151100622 T CY151100622 T CY 151100622T CY 1116842 T1 CY1116842 T1 CY 1116842T1
Authority
CY
Cyprus
Prior art keywords
humanized antibodies
proteinological
beta
amyloid peptide
specifically humanized
Prior art date
Application number
CY20151100622T
Other languages
English (en)
Inventor
Nicolas Baurin
Francis Blanche
Béatrice Cameron
Marc Duchesne
Vincent Mikol
Souad Naimi
Laurent Pradier
Yi Shi
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116842(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1116842T1 publication Critical patent/CY1116842T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ειδικά εξανθρωπισμένα αντισώματα στην πρωτοϊνιδιακή μορφή του β-αμυλοειδούς πεπτιδίου, και με την χρήση αυτών των αντισωμάτων στο πεδίο της νόσου Alzheimer.
CY20151100622T 2009-05-12 2015-07-14 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου CY1116842T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0953133A FR2945538B1 (fr) 2009-05-12 2009-05-12 Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP10728743.5A EP2430049B1 (fr) 2009-05-12 2010-05-11 Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Publications (1)

Publication Number Publication Date
CY1116842T1 true CY1116842T1 (el) 2017-03-15

Family

ID=41591699

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100622T CY1116842T1 (el) 2009-05-12 2015-07-14 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY20181100343T CY1120413T1 (el) 2009-05-12 2018-03-27 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181100343T CY1120413T1 (el) 2009-05-12 2018-03-27 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Country Status (41)

Country Link
US (4) US8614299B2 (el)
EP (3) EP3050898B1 (el)
JP (2) JP2012526541A (el)
KR (1) KR101783058B1 (el)
CN (1) CN102459336B (el)
AR (1) AR076670A1 (el)
AU (1) AU2010247215B2 (el)
BR (1) BRPI1012853B1 (el)
CA (1) CA2761665A1 (el)
CL (1) CL2011002831A1 (el)
CO (1) CO6460745A2 (el)
CR (1) CR20110585A (el)
CY (2) CY1116842T1 (el)
DK (2) DK2977385T3 (el)
EA (1) EA028357B1 (el)
EC (1) ECSP11011452A (el)
ES (2) ES2542757T3 (el)
FR (1) FR2945538B1 (el)
GT (1) GT201100283A (el)
HR (3) HRP20150776T1 (el)
HU (1) HUE036737T2 (el)
IL (1) IL216237B (el)
LT (1) LT2977385T (el)
MA (1) MA33350B1 (el)
MX (1) MX2011012060A (el)
MY (1) MY159398A (el)
NI (1) NI201100195A (el)
NZ (1) NZ596540A (el)
PE (1) PE20120906A1 (el)
PL (2) PL2977385T3 (el)
PT (2) PT2977385T (el)
RS (1) RS54122B1 (el)
SG (1) SG176155A1 (el)
SI (2) SI2430049T1 (el)
SV (1) SV2011004058A (el)
TN (1) TN2011000571A1 (el)
TW (2) TWI542360B (el)
UA (1) UA107574C2 (el)
UY (1) UY32633A (el)
WO (1) WO2010130946A1 (el)
ZA (1) ZA201108301B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2207568T1 (sl) 2007-11-16 2017-11-30 The Rockefeller University Protitelesa specifična za protifibrilno obliko beta-amiloidnega proteina
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
JP6463331B2 (ja) 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
MX2017001531A (es) 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
CA2991856A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
WO2017040301A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
KR20180084817A (ko) 2015-10-29 2018-07-25 알렉터 엘엘씨 항-siglec-9 항체 및 이의 이용 방법
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN110662765B (zh) 2017-08-03 2023-09-29 艾利妥 抗cd33抗体及其使用方法
RS64419B1 (sr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 antitela i postupci za njihovu upotrebu
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
JP7382970B2 (ja) 2018-06-08 2023-11-17 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
EA202190183A1 (ru) 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения
AU2019331018A1 (en) 2018-08-31 2021-03-11 Alector Llc Anti-cd33 antibodies and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
US20220356233A1 (en) * 2019-08-20 2022-11-10 The Curators Of The University Of Missouri Amyloid-beta antibodies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020403021A1 (en) 2019-12-12 2022-06-23 Alector Llc Methods of use of anti-CD33 antibodies
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2022046644A1 (en) 2020-08-25 2022-03-03 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting hiv and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
ATE510850T1 (de) * 2000-09-15 2011-06-15 Coley Pharm Gmbh Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
PT1674111E (pt) * 2004-07-09 2010-12-15 Chugai Pharmaceutical Co Ltd Anticorpo anti-glipicano 3
CA2575663C (en) * 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2007108755A1 (en) * 2006-03-22 2007-09-27 Gyros Patent Ab Plex method
RS51723B2 (sr) * 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
DK2099826T3 (da) * 2007-01-05 2014-01-20 Univ Zuerich Anti-beta-amyloid-antistof og anvendelser deraf
AU2008221118B2 (en) * 2007-03-01 2013-10-03 Les Laboratoires Servier Recombinant anti-epidermal growth factor receptor antibody compositions
MY159201A (en) 2007-08-29 2016-12-30 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
SI2207568T1 (sl) * 2007-11-16 2017-11-30 The Rockefeller University Protitelesa specifična za protifibrilno obliko beta-amiloidnega proteina
DK3211005T3 (da) * 2008-07-08 2021-06-07 Geneuro Sa Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
DK3138854T3 (da) * 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
CA2754743C (en) * 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Also Published As

Publication number Publication date
FR2945538B1 (fr) 2014-12-26
CY1120413T1 (el) 2019-07-10
US20160368977A1 (en) 2016-12-22
LT2977385T (lt) 2018-04-10
DK2430049T3 (en) 2015-07-20
US20140105890A1 (en) 2014-04-17
GT201100283A (es) 2013-11-07
ES2664409T3 (es) 2018-04-19
CO6460745A2 (es) 2012-06-15
EP3050898B1 (fr) 2018-08-15
ECSP11011452A (es) 2011-12-30
ZA201108301B (en) 2013-01-30
MA33350B1 (fr) 2012-06-01
KR101783058B1 (ko) 2017-09-28
TW201641690A (zh) 2016-12-01
JP2016028591A (ja) 2016-03-03
EP2430049A1 (fr) 2012-03-21
EP3050898A1 (fr) 2016-08-03
US8614299B2 (en) 2013-12-24
CN102459336B (zh) 2016-04-20
HRP20180516T1 (hr) 2018-05-04
EP2977385A1 (fr) 2016-01-27
ES2542757T3 (es) 2015-08-11
HRP20150776T1 (hr) 2015-08-28
PL2977385T3 (pl) 2018-06-29
EA028357B1 (ru) 2017-11-30
JP2012526541A (ja) 2012-11-01
PT2430049E (pt) 2015-09-01
FR2945538A1 (fr) 2010-11-19
AR076670A1 (es) 2011-06-29
US20120177639A1 (en) 2012-07-12
US9382312B2 (en) 2016-07-05
UA107574C2 (ru) 2015-01-26
NZ596540A (en) 2013-05-31
EA201171388A1 (ru) 2012-05-30
EP2430049B1 (fr) 2015-04-15
AU2010247215B2 (en) 2015-08-20
IL216237B (en) 2018-05-31
CN102459336A (zh) 2012-05-16
TN2011000571A1 (fr) 2013-05-24
US20190119365A1 (en) 2019-04-25
WO2010130946A1 (fr) 2010-11-18
TWI583791B (zh) 2017-05-21
CR20110585A (es) 2011-12-07
BRPI1012853B1 (pt) 2021-08-24
EP2977385B1 (fr) 2017-12-27
MX2011012060A (es) 2012-04-30
US10112991B2 (en) 2018-10-30
CA2761665A1 (fr) 2010-11-18
MY159398A (en) 2016-12-30
PT2977385T (pt) 2018-04-03
SI2430049T1 (sl) 2015-08-31
PL2430049T3 (pl) 2015-09-30
DK2977385T3 (en) 2018-04-16
SV2011004058A (es) 2012-06-06
TWI542360B (zh) 2016-07-21
SI2977385T1 (en) 2018-05-31
RS54122B1 (sr) 2015-12-31
HRP20181985T1 (hr) 2019-01-25
HUE036737T2 (hu) 2018-07-30
TW201100102A (en) 2011-01-01
PE20120906A1 (es) 2012-08-08
IL216237A0 (en) 2012-01-31
NI201100195A (es) 2012-02-01
JP6310895B2 (ja) 2018-04-11
KR20120096950A (ko) 2012-08-31
CL2011002831A1 (es) 2012-05-11
BRPI1012853A2 (pt) 2018-06-19
SG176155A1 (en) 2011-12-29
AU2010247215A1 (en) 2011-12-15
UY32633A (es) 2010-12-31
HK1167152A1 (en) 2012-11-23

Similar Documents

Publication Publication Date Title
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1123404T1 (el) Αντι-girt αντισωματα
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
MX338754B (es) Anticuerpos humanos contra el factor tisular.
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
UA107836C2 (uk) Метод лікування хвороби альцгеймера
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
UA111322C2 (uk) Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування
TH128722A (th) ฮิวมาไนซ์แอนติบอดีที่จำเพาะต่อรูปโปรโตไฟบริลลาร์ของบีตา-อมัยลอยด์เพพไทด์
CY1116623T1 (el) Συνθεσεις και μεθοδοι για αντισωματα κατα της πρωτεϊνης c5 συμπληρωματος
CY1115158T1 (el) Ραδιοανοσοσυζευγματα και χρησεις αυτων